Chardan Capital analyst Gbola Amusa reiterated a Buy rating on uniQure NV (NASDAQ: QURE) today and set a price target of $50. The company’s shares closed yesterday at $28.99.
“We note organ-specific promoters will help mitigate toxicity issues associated with off-target expression of transgenes. In addition, better promoters means potentially lower dosage of vector genomes will be required to achieve therapeutic levels of therapeutic protein levels.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 21.2% and a 48.0% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for uniQure NV with a $51.50 average price target, implying a 77.6% upside from current levels. In a report issued on October 3, Cantor Fitzgerald also maintained a Buy rating on the stock with a $58 price target.
See today’s analyst top recommended stocks >>
Based on uniQure NV’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.59 million. In comparison, last year the company had a GAAP net loss of $10.25 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.